167 related articles for article (PubMed ID: 22382554)
1. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.
Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors.
Xin Y; Li J; Wu J; Kinard R; Weekes CD; Patnaik A; Lorusso P; Brachmann R; Tong RK; Yan Y; Watts R; Bai S; Hegde PS
Clin Cancer Res; 2012 Nov; 18(21):6040-8. PubMed ID: 22962439
[TBL] [Abstract][Full Text] [Related]
3. Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans.
Xin Y; Bai S; Damico-Beyer LA; Jin D; Liang WC; Wu Y; Theil FP; Joshi A; Lu Y; Lowe J; Maia M; Brachmann RK; Xiang H
Pharm Res; 2012 Sep; 29(9):2512-21. PubMed ID: 22707361
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.
Weekes CD; Beeram M; Tolcher AW; Papadopoulos KP; Gore L; Hegde P; Xin Y; Yu R; Shih LM; Xiang H; Brachmann RK; Patnaik A
Invest New Drugs; 2014 Aug; 32(4):653-60. PubMed ID: 24604265
[TBL] [Abstract][Full Text] [Related]
5. Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.
Bumbaca D; Xiang H; Boswell CA; Port RE; Stainton SL; Mundo EE; Ulufatu S; Bagri A; Theil FP; Fielder PJ; Khawli LA; Shen BQ
Br J Pharmacol; 2012 May; 166(1):368-77. PubMed ID: 22074316
[TBL] [Abstract][Full Text] [Related]
6. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
7. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
[TBL] [Abstract][Full Text] [Related]
8. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
[TBL] [Abstract][Full Text] [Related]
9. Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.
Dudal S; Subramanian K; Flandre T; Law WS; Lowe PJ; Skerjanec A; Genin JC; Duval M; Piequet A; Cordier A; Jarai G; Van Heeke G; Taplin S; Krantz C; Jones S; Warren AP; Brennan FR; Sims J; Lloyd P
MAbs; 2015; 7(5):829-37. PubMed ID: 26230385
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
[TBL] [Abstract][Full Text] [Related]
11. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against
Deng R; Zhou C; Li D; Cai H; Sukumaran S; Carrasco-Triguero M; Saad O; Nazzal D; Lowe C; Ramanujan S; Kamath AV
MAbs; 2019; 11(6):1162-1174. PubMed ID: 31219754
[TBL] [Abstract][Full Text] [Related]
13. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
Patnaik A; LoRusso PM; Messersmith WA; Papadopoulos KP; Gore L; Beeram M; Ramakrishnan V; Kim AH; Beyer JC; Mason Shih L; Darbonne WC; Xin Y; Yu R; Xiang H; Brachmann RK; Weekes CD
Cancer Chemother Pharmacol; 2014 May; 73(5):951-60. PubMed ID: 24633809
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.
Wang W; Wang X; Doddareddy R; Fink D; McIntosh T; Davis HM; Zhou H
AAPS J; 2014 Jan; 16(1):129-39. PubMed ID: 24287601
[TBL] [Abstract][Full Text] [Related]
15. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
[TBL] [Abstract][Full Text] [Related]
16. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
[TBL] [Abstract][Full Text] [Related]
18. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
[TBL] [Abstract][Full Text] [Related]
20. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
